Nadine Opgen-Rhein

OpGen Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Nadine Opgen-Rhein, Medicine, FDA, Marketing, Infection, Phase 10, Public utility, Vaccine, Video game, Security (finance)

Third Quarter 2023 Financial Results of OpGen, Inc.

Key Points: 
  • Third Quarter 2023 Financial Results of OpGen, Inc.
    Total revenue for the third quarter of 2023 was approximately $0.70 million compared to the Company’s revenue of approximately $0.45 million in the third quarter of 2022.
  • Total operating expenses decreased in the third quarter of 2023 to approximately $4.26 million compared to approximately $13.96 million for the third quarter of 2022 primarily due to the Company’s goodwill impairment charge of $6.98 million recorded in the third quarter of 2022.
  • Cash and cash equivalents were approximately $0.29 million as of September 30, 2023, compared with approximately $7.44 million as of December 31, 2022.
  • In October 2023, OpGen discontinued its FDA cleared Acuitas AMR Gene Panel diagnostic test.

OpGen Enters Into Warrant Inducement Transaction for up to $11.2 Million in Gross Proceeds

Retrieved on: 
Thursday, October 12, 2023
Nadine Opgen-Rhein, Sale, Medicine, Informatics, Infection, Exercise, Security (finance)

As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.

Key Points: 
  • As part of the agreement, the existing holder has agreed to pay an additional $0.25 consideration per share, resulting in gross proceeds of up to approximately $11.2 million, assuming full exercise of the existing warrants and before deducting offering fees and expenses.
  • A.G.P./Alliance Global Partners acted as the exclusive financial advisor in connection with the transaction.
  • The New Warrants are immediately exercisable upon issuance at an exercise price of $0.336 per common share and will expire on October 16, 2028.
  • The Company has agreed to file a registration statement with the SEC covering the resale of common shares issuable upon exercise of the New Warrants.

OpGen Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Communication, De novo, Classification, Nucleotide, UTI, European Patent Office, Infection, Curetis, Thermo Fisher Scientific, AMR, IP, Sale, Nadine Opgen-Rhein, Single-nucleotide polymorphism, Urinary tract infection, Patent, SNP, Medicine, European Patent Convention, Plasmid, IVD, FDA, Ares, Pneumonia, Video game, Pharmaceutical industry, Q2

ET

Key Points: 
  • ET
    ROCKVILLE, Md., Aug. 10, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its second quarter and first half of 2023 financial and operating results.
  • Second Quarter 2023 and First Half 2023 Financial Results of OpGen, Inc.
    Total revenue for the second quarter of 2023 was approximately $0.7 million compared to the company’s revenue of approximately $1.0 million in the second quarter of 2022, which was primarily driven by the one-time sale of a pool of Unyvero instrument systems to Menarini in Q2-2022.
  • Total operating expenses decreased in the second quarter of 2023 to approximately $5.9 million compared to approximately $6.2 million for the second quarter of 2022.
  • ET, to review the second quarter 2023 financial results and business activities, but will not be taking any questions.

OpGen’s Subsidiary Ares Genetics Releases New Features to its AREScloud Offering

Retrieved on: 
Monday, August 7, 2023
Informatics, SOCS2, Infection, Genomics, AMR, Nadine Opgen-Rhein, Houston, Laboratory, SNP, Medicine, Plasmid, WGS, Health, Ares, HIPAA, Vaccine, Antibiotics, Q3

Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.

Key Points: 
  • Working with its customers globally, the Ares team has developed the new AREScloud features to provide relevant reporting for hospital epidemiologists and infection preventionists.
  • The new AREScloud features are now deployed as part of the standard analysis package, and in use with our customers globally.
  • The new features further broaden the capabilities of AREScloud for microbial genomics that include antimicrobial resistance profiling, and genomic antibiotic sensitivity testing.
  • To support this goal, we continue to enhance our AREScloud features, while making pathogen sequencing both affordable and broadly available.”

OpGen’s Subsidiary Curetis and FIND Extend R&D Collaboration Agreement

Retrieved on: 
Thursday, August 3, 2023
Infection, A30, Curetis, Research, AMR, LMIC, Hospital, Medicine, IVD, Blood culture, Nadine Opgen-Rhein, Medical device, Developing country

This extended R&D collaboration now covers the development of an AMR assay and Unyvero A30 cartridge for AMR detection from commonly used blood culture bottles as well as the corresponding software plugin development and full analytical performance evaluation.

Key Points: 
  • This extended R&D collaboration now covers the development of an AMR assay and Unyvero A30 cartridge for AMR detection from commonly used blood culture bottles as well as the corresponding software plugin development and full analytical performance evaluation.
  • Andreas Boos, Chief Technology Officer at Curetis GmbH and program manager for the Unyvero A30 platform development commented, “We are excited to begin working on this new contract and continue our collaboration project.
  • We are focused on making sure diagnostics are accessible to prevent further development of AMR.
  • The Unyvero A30 platform and the AMR test being developed on it has the potential to meet the requirements for use in low- and middle-income countries.

OpGen to Provide Business Update and Financial Results for the Second Quarter 2023 on August 10th at 4:30 p.m. Eastern Time

Retrieved on: 
Thursday, August 3, 2023
Nadine Opgen-Rhein, Rare-earth element, Cryptocurrency

ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023.

Key Points: 
  • ROCKVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2023 financial results after the close of the U.S. financial markets on Thursday, August 10th 2023.
  • OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide an update on business activities.

OpGen’s Subsidiary Curetis Meets Milestones of Extended and Expanded R&D Collaboration with FIND

Retrieved on: 
Wednesday, July 19, 2023
NGS, Infection, A30, Curetis, Research, AMR, Global Health Innovative Technology Fund, IP, LMIC, Hospital, Medicine, Nadine Opgen-Rhein, Ares, Medical device, Developing country

Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.

Key Points: 
  • Following the delivery of a comprehensive milestone report at the end of the second quarter of 2023, FIND recently confirmed that all requirements have been met successfully.
  • This deliverable supports usage of Unyvero A30 test data in resource-constrained settings with minimal infrastructure as often faced in many LMICs.
  • This analysis revealed important differences in the sequences of clinically relevant bacterial strains between those coming from LMICs versus those obtained in Western countries.
  • Dr. Gerd Luedke, Director Innovation, Technology and IP at Curetis GmbH commented, “We are excited to have successfully delivered on all of the milestones from the expanded and extended phase of our collaboration agreement.

OpGen Subsidiary Ares Genetics Successfully Maintains Key Patent under Opposition in Europe

Retrieved on: 
Monday, June 26, 2023
Informatics, Patent, Database, Nucleotide, Infection, European Patent Office, Opposition procedure before the European Patent Office, Genomics, AMR, Nadine Opgen-Rhein, Genetics, Machine learning, Hearing, Medicine, European Patent Convention, WGS, Diagnosis, Antibiotics, Generic drug, Vaccine

The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications.

Key Points: 
  • The opposition division of European Patent Office ruled to maintain the patent as granted with minor modifications.
  • ROCKVILLE, Md., June 26, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, and OpGen subsidiary, Ares Genetics, which strives to become a leader in bacterial genomics and AI-powered prediction of antimicrobial resistance (AMR), announced today that one of its key patents under opposition has been successfully maintained.
  • In September 2021, an opposition was filed by a Swedish opponent against the patent grant by the European Patent Office.
  • In a hearing on Thursday, June 22, 2023, the opposition division of the European Patent Office ruled in favor of maintaining the patent as granted with a minor amendment to one of the claims.

OpGen’s Subsidiary Curetis Receives Batch of Ten New C-Series Unyvero A30 Instruments

Retrieved on: 
Thursday, June 22, 2023
Nadine Opgen-Rhein, Infection, A30, AMR, Medicine, Medical device

The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.

Key Points: 
  • The instruments have successfully passed electrical and functional testing and will allow rapid sample-to-answer molecular testing with numerous chemistries and assay formats.
  • These C-Series instruments incorporate all learnings from extensive testing of the 10 B-Series instruments over the past 12 months.
  • They have also been optimized for extended lifetime of all key moving parts inside the instruments, as well as cost of goods in the manufacturing process of these A30 instruments.
  • Andreas Boos, CTO of Curetis and program lead of the Unyvero A30 platform project commented: “We are excited to have taken possession of this newest batch of instruments.

OpGen Presents Unyvero Urinary Tract Infection Panel Trial Results at ASM Microbe 2023 Conference

Retrieved on: 
Tuesday, June 20, 2023
Communication, University, De novo, Classification, UTI, Culture, Infection, Clinical trial, System, ASM, Research, Federal, Nadine Opgen-Rhein, Investigational device exemption, Medicine, ITI, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Microbiology, Medical imaging, Vaccine

OpGen’s Unyvero UTI panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.

Key Points: 
  • OpGen’s Unyvero UTI panel tests for a broad range of bacterial and fungal pathogens as well as antimicrobial resistance markers directly from urine specimens.
  • OpGen is seeking marketing authorization for its Unyvero UTI panel.
  • “Our data demonstrated that the Unyvero UTI panel covered nearly 94% of all organisms identified in standard of care microbiology culture.
  • Performance characteristics for this device have not yet been established and the FDA has not yet cleared the panel.